Company / Net Income
Eledon Pharmaceuticals, Inc. Net Income History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$23.3M
FY2016
5-year range
-$23.3M / -$9.6M
FY2014-FY2016
Trend
-48.1%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$10M to -$23M over the past 2 years.
Based on SEC 10-K filings.
-$23M in FY2016.
Declined from -$10M to -$23M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, net income decreased 48.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | -$23.3M | -48.1% |
| FY2015 | -$15.7M | -63.0% |
| FY2014 | -$9.6M | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026